A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof:

##STR00001##

wherein is a single or double bond, X is NCH.sub.3 or CH.sub.2, Y is null, O or N, Z is O or N, R.sub.1 is H, OH, and R.sub.2 is null, H, C.sub.1-C.sub.8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO.sub.2, —NH.sub.2, —NR.sub.3R.sub.4, carbonyl, alkoxyl, alkyl or —OCF.sub.3, wherein R.sub.3 and R.sub.4 independently are H, alkyl, O.sub.2CH.sub.3, —(C═O)—CH.sub.3 or (C═O)—NH.sub.2.

A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.

A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: ##STR00001##
wherein is a single or double bond, X is NCH.sub.3 or CH.sub.2, Y is null, O or N, Z is O or N, R.sub.1 is H, OH, and R.sub.2 is null, H, C.sub.1-C.sub.8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO.sub.2, —NH.sub.2, —NR.sub.3R.sub.4, carbonyl, alkoxyl, alkyl or —OCF.sub.3, wherein R.sub.3 and R.sub.4 independently are H, alkyl, —SO.sub.2CH.sub.3, —(C═O)—CH.sub.3 or —(C═O)—NH.sub.2.

A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: ##STR00001##
wherein is a single or double bond, X is NCH.sub.3 or CH.sub.2, Y is null, O or N, Z is O or N, R.sub.1 is H, OH, and R.sub.2 is null, H, C.sub.1-C.sub.8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO.sub.2, —NH.sub.2, —NR.sub.3R.sub.4, carbonyl, alkoxyl, alkyl or —OCF.sub.3, wherein R.sub.3 and R.sub.4 independently are H, alkyl, —SO.sub.2CH.sub.3, —(C═O)—CH.sub.3 or —(C═O)—NH.sub.2.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.

##STR00001##

The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound for use in the activation of AMPK is also provided.

The present disclosure provides safe and effective dosing regimens of metal chelators as treatment for metal overload disorders and, in particular, iron overload and associated conditions.